Verge Labs
PrivateLast Round
Strategic
Sep 8, 2023
Est. Valuation
$1.71M
Total Funding Raised
$134.12M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Verge Labs is a biotechnology company that provides drug developers with an AI-powered platform and proprietary patient genomic datasets to identify therapeutic targets for neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verge Labs Comparables
Compare Verge Labs with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 1910 Genetics | 82% | |
| AcuraStem | 82% | |
| Argo Therapeutics | 81% |
Verge Labs Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Sep 8, 2023 | ||||
| Series B | Dec 16, 2021 | ||||
| Strategic | Jul 8, 2021 | ||||
| Series A | Jul 16, 2018 | ||||
| Seed | Oct 28, 2015 | ||||
Accelerator | Jul 21, 2015 |
Verge Labs Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Slow Ventures | Seed |
| S32 | Series B |
| Agent Capital | Series A |
| Great Oaks Venture Capital | Seed |
| Threshold Ventures | Series B |
| DFJ Ventures | Series A |
| Lifeforce Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 23, 2026
Eli Lilly and AstraZeneca partnerships exceed $1.6B.
- Feb 23, 2026
Two unnamed drugs have been delivered to the clinic.
Recent news
Latest coverage and updates
- receives_financingJun 25, 2026
Verge Genomics, Inc. receives financing of $116M in Series B.
Verge Labs Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Verge Labs's valuation, stock price, and market status.
Is Verge Genomics a public or private company?
Verge Genomics is a private company.
What is the current stock price of Verge Genomics?
Verge Genomics is a private company with no public stock price. No recent secondary market data is available.
How much is Verge Genomics worth (valuation)?
Verge Genomics's valuation is estimated at $1.7M based on funding round data.
Can I buy Verge Genomics stock?
Verge Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Verge Genomics's last funding round?
Verge Genomics's most recent funding round was Series B on July 21, 2015.
Who are the main investors in Verge Genomics?
Key investors in Verge Genomics include Great Oaks Venture Capital, DFJ Ventures, Two Sigma Ventures, IA Ventures, Draper Fisher Jurvetson Management.
Will Verge Genomics IPO soon?
No public IPO plans have been announced for Verge Genomics.
How can I track Verge Genomics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Verge Genomics's secondary market activity and sign up for updates.